KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amneal Pharmaceuticals (AMRX) FCF Margin (2017 - 2026)

Amneal Pharmaceuticals has reported FCF Margin over the past 9 years, most recently at 13.33% for Q4 2025.

  • For Q4 2025, FCF Margin fell 76.0% year-over-year to 13.33%; the TTM value through Dec 2025 reached 8.94%, up 24.0%, while the annual FY2025 figure was 8.94%, 24.0% up from the prior year.
  • FCF Margin for Q4 2025 was 13.33% at Amneal Pharmaceuticals, down from 13.53% in the prior quarter.
  • Over five years, FCF Margin peaked at 27.65% in Q1 2021 and troughed at 23.34% in Q2 2022.
  • A 5-year average of 8.23% and a median of 12.29% in 2023 define the central range for FCF Margin.
  • Biggest five-year swings in FCF Margin: crashed -4790bps in 2021 and later surged 2612bps in 2023.
  • Year by year, FCF Margin stood at 8.52% in 2021, then tumbled by -167bps to 5.7% in 2022, then surged by 458bps to 20.42% in 2023, then crashed by -31bps to 14.09% in 2024, then dropped by -5bps to 13.33% in 2025.
  • Business Quant data shows FCF Margin for AMRX at 13.33% in Q4 2025, 13.53% in Q3 2025, and 8.42% in Q2 2025.